These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21258822)

  • 41. Characterisation of tramadol, morphine and tapentadol in an acute pain model in Beagle dogs.
    Kögel B; Terlinden R; Schneider J
    Vet Anaesth Analg; 2014 May; 41(3):297-304. PubMed ID: 24576316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does 'Strong Analgesic' Equal 'Strong Opioid'? Tapentadol and the Concept of 'µ-Load'.
    Raffa RB; Elling C; Tzschentke TM
    Adv Ther; 2018 Oct; 35(10):1471-1484. PubMed ID: 30206823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy.
    Niesters M; Proto PL; Aarts L; Sarton EY; Drewes AM; Dahan A
    Br J Anaesth; 2014 Jul; 113(1):148-56. PubMed ID: 24713310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Tapentadol. Opioid analgesic and norepinephrine reuptake inhibitors].
    Weichel C; Hecht B
    Med Monatsschr Pharm; 2010 Dec; 33(12):454-60. PubMed ID: 21189520
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacological rationale for tapentadol therapy: a review of new evidence.
    Romualdi P; Grilli M; Canonico PL; Collino M; Dickenson AH
    J Pain Res; 2019; 12():1513-1520. PubMed ID: 31190962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Efficacy of Tapentadol for Neuropathic Pain in Cancer].
    Takahara Y; Tanahashi J; Murota K; Imai M; Takagi Y; Kimata T
    Gan To Kagaku Ryoho; 2021 Jun; 48(6):811-814. PubMed ID: 34139729
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol.
    Munro G; Baek CA; Erichsen HK; Nielsen AN; Nielsen EØ; Scheel-Kruger J; Weikop P; Peters D
    Neuropharmacology; 2008 Feb; 54(2):331-43. PubMed ID: 18037451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tapentadol prolonged release in the treatment of musculoskeletal pain: an innovative pharmacological option.
    Marinangeli F; Evangelista M; Finco G
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):5-13. PubMed ID: 31755079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain.
    Christoph T; De Vry J; Schiene K; Tallarida RJ; Tzschentke TM
    Eur J Pharmacol; 2011 Sep; 666(1-3):72-9. PubMed ID: 21640095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacology update: tapentadol for neuropathic pain.
    Pierce DM; Shipstone E
    Am J Hosp Palliat Care; 2012 Dec; 29(8):663-6. PubMed ID: 22310021
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanistic and functional differentiation of tapentadol and tramadol.
    Raffa RB; Buschmann H; Christoph T; Eichenbaum G; Englberger W; Flores CM; Hertrampf T; Kögel B; Schiene K; Straßburger W; Terlinden R; Tzschentke TM
    Expert Opin Pharmacother; 2012 Jul; 13(10):1437-49. PubMed ID: 22698264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Tapentadol is a new, strongly efficative analgeticum with dual effect mechanisms].
    Staahl C; Drewes AM; Jensen NH
    Ugeskr Laeger; 2011 Jun; 173(25):1796-9. PubMed ID: 21689507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
    Frampton JE
    Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.
    Lei W; Vekariya RH; Ananthan S; Streicher JM
    J Pain; 2020; 21(1-2):146-160. PubMed ID: 31201990
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Commentary on: Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain.
    Dickenson AH
    Neurosci Lett; 2014 Mar; 562():90. PubMed ID: 24121047
    [No Abstract]   [Full Text] [Related]  

  • 56. Tapentadol shows lower intrinsic efficacy at µ receptor than morphine and oxycodone.
    Manandhar P; Connor M; Santiago M
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00921. PubMed ID: 35084120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of tapentadol on mechanical hypersensitivity in rats with ligatures of the infraorbital nerve versus the sciatic nerve.
    Michot B; Bourgoin S; Kayser V; Hamon M
    Eur J Pain; 2013 Jul; 17(6):867-80. PubMed ID: 23229959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.
    Baron R; Eberhart L; Kern KU; Regner S; Rolke R; Simanski C; Tölle T
    Pain Pract; 2017 Jun; 17(5):678-700. PubMed ID: 27611642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monoamine-dependent, opioid-independent antihypersensitivity effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a postoperative pain model in rats.
    Obata H; Kimura M; Nakajima K; Tobe M; Nishikawa K; Saito S
    J Pharmacol Exp Ther; 2010 Sep; 334(3):1059-65. PubMed ID: 20558774
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spinal neuronal correlates of tapentadol analgesia in cancer pain: a back-translational approach.
    Falk S; Patel R; Heegaard A; Mercadante S; Dickenson AH
    Eur J Pain; 2015 Feb; 19(2):152-8. PubMed ID: 24917026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.